The Pharmaceutical Rivalry Behind the Weight-Loss Drug Boom
Novo Nordisk’s Wegovy had the first-mover advantage, but Eli Lilly’s Zepbound is poised to be even bigger. On today’s Big Take podcast, we share the tale of two pharmaceutical companies taking on the $80 billion weight-loss drug market.
Photographer: agrobacter/E+/Getty Images
Listen to The Big Take podcast on iHeart, Apple Podcasts, Spotify and the Bloomberg Terminal.
The multi-billion dollar weight-loss drug market has ballooned in the past few years. And the two pharmaceutical companies currently duking it out for market dominance, Novo Nordisk and Eli Lilly, have a century-long rivalry. In today’s episode, Bloomberg News health reporter Madison Muller breaks down how Eli Lilly developed Zepbound, a new drug that can help patients cut more than 20% of their body weight — and why some investors and analysts say it could turn Eli Lilly into the first ever trillion-dollar drug company.